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Protein tyrosine phosphatase receptor type Q (PTPRQ) is an unusual PTP that has
intrinsic dephosphorylating activity for various phosphatidyl inositides instead of
phospho-tyrosine substrates. Although PTPRQ was known to be involved in the
pathogenesis of obesity, no small-molecule inhibitor has been reported so far. Here
we report six novel PTPRQ inhibitors identified with computer-aided drug design
protocol involving the virtual screening with docking simulations and enzyme
inhibition assay. These inhibitors exhibit moderate potencies against PTPRQ with the
associated IC50 values ranging from 29 to 86 μM. Because the newly discovered
inhibitors were also computationally screened for having desirable physicochemical
properties as a drug candidate, they deserve consideration for further development
by structure-activity relationship studies to optimize the antiobestic activities.
Structural features relevant to the stabilization of the inhibitors in the active site of
PTPRQ are addressed in detail.
Keywords: Virtual screening, PTPRQ, Inhibitor, Docking, Antiobestic agentsIntroduction
Protein tyrosine phosphatases (PTPs) catalyze the hydrolysis of the phosphorylated
tyrosine residues of protein substrates, which is a hallmark of cellular signal transduc-
tion. Because these dephosphorylation activities of PTPs have been implicated in a variety
of cellular processes, abnormal PTP activities may cause various diseases including
cancer, diabetes, and immune deficiencies [1]. Total 38 members of PTP family (21
receptor-type PTPs and 17 nonreceptor-type PTPs) are known to have specificity for the
phosphorylated tyrosine substrates [2]. Most PTPs share a highly conserved catalytic
module that plays a crucial role in the enzymatic action for dephosphorylation reaction.
This catalytic core comprises a PTP loop (Cys-Ser-Xaa-Gly-Xaa-Gly-Arg-Thr/Ser), WPD
loop, and Q loop [3]. The invariant cysteine is located at the bottom of the PTP loop to
act as a nucleophile to attack the substrate phosphorous atom, while the side-chain
guanidinium ion of the conserved Arg residue in the PTP loop stabilizes the negative
charge on the oxygen atoms of the substrate accumulated during the hydrolysis reaction.
The conserved Gln and Asp residues in the Q and WPD loops also participate in the
hydrolysis reaction of the substrate through the role of a general acid/base catalyst [3].© 2013 Park et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
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tains 18 extracellular fibronectin domains and one cytoplasmic catalytic domain. Al-
though the primary sequence of the catalytic domain of PTPRQ (PTPRQ-C) shows a
high degree of similarity to those of the known PTPs, PTPRQ displays an unusual cata-
lytic behavior. For example, it has intrinsic dephosphorylating activity for various phos-
phatidyl inositides (PIs) but not for phospho-tyrosine substrates [4]. Furthermore,
PTPRQ negatively regulates the proliferation and survival of cells by lowering the level
of phosphoinositol phosphates (PIPs) [5]. This characteristic dephosphorylating activity
can be attributed in a large part to the difference in amino-acid sequence of the WPD
loop in which the conserved aspartate is replaced with a glutamate. This hypothesis
was supported by the experimental finding that the reverse mutation of glutamate to
aspartate in the WPE motif caused PTPRQ to gain catalytic activity toward pTyr while
losing the activity with respect to PI substrates [5]. Four catalytically active members of
the classical PTP family (PTPRQ, PTPRU, PTPD1 and HDPTP) in human genome pos-
sess the WPE motif instead of the WPD one, the structures of which have not charac-
terized yet except for PTPRQ. PTPRQ is also homologous to a few PTPs such as
phosphatase and tensin homolog (PTEN) and myotubularin phosphatases, which have
the catalytic capability to dephosphorylate PIs [2]. A line of experimental evidence
showed that the loss of PTPRQ gene could lead to the hearing impairment associated
with vestibular dysfunction [6-8]. It was also demonstrated that the overexpression of
PTPRQ caused the differentiation of mesenchymal stem cells (MSCs) into adipocytes,
which leads to the pathogenesis of obesity [9]. This indicates that PTPRQ can serve as
an effective target for development of new antiobestic drugs.
Very recently, X-ray crystal structure of human PTPRQ has been reported in com-
plex with the sulfate ion bound in the active site as a surrogate for the phosphate group
of substrates [10]. In this structure, PTPRQ adopts an open conformation in which the
residues of WPE loop stay distant from the active site. It has a flatter active site than
other PTPs to accommodate the PIP substrates that are larger than the phosphorylated
tyrosine. The presence of structural information about the nature of the interactions
between PTPRQ and small-molecule ligands can make it a plausible task to design the
potent inhibitors that may develop into an antiobestic drug. Nonetheless, the discovery
of PTPRQ inhibitors has lagged behind the biological and structural studies. To the
best of our knowledge, no small-molecule PTPRQ inhibitor has been reported so far in
the literature at least. In this paper, we report the novel classes of PTPRQ inhibitors
identified through the structure-based drug design protocol involving the virtual
screening with docking simulations and in vitro enzyme assay. Computer-aided drug
design has not always been successful due to the inaccuracy in the scoring function,
which leads to a weak correlation between the computational predictions and experi-
mental results for binding affinities [11]. Therefore, we implement an accurate solv-
ation free energy function into the scoring function to enhance the accuracy in
calculating the binding free energies between PTPRQ and the putative inhibitors. This
modification of the scoring function seems to improve the potential for designing the
new inhibitors with high activity [12]. It will be shown that docking simulations with
the improved binding free energy function can be a useful tool for enriching the chem-
ical library with molecules that are likely to have desired biological activities, as well as
for elucidating the activities of the identified inhibitors.
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3D atomic coordinates in the X-ray crystal structure of human PTPRQ in complex with
the sulfate ion as a substrate analogue (PDB code: 4ikc) were selected as the receptor
model in the virtual screening. After removing the crystallographic water molecules,
hydrogen atoms were added to each protein atom. A special attention was paid to assign
the protonation states of the ionizable Asp, Glu, His, and Lys residues in the original X-
ray structure of PTPRQ. The side chains of Asp and Glu residues were assumed to be
neutral if one of their carboxylate oxygens pointed toward a hydrogen-bond accepting
group including the backbone aminocarbonyl oxygen at a distance within 3.5 Å, a gener-
ally accepted distance limit for a hydrogen bond of moderate strength [13]. Similarly, the
lysine side chains were assumed to be protonated unless the NZ atom was in proximity of
a hydrogen-bond donating group. The same procedure was also applied to determine the
protonation states of ND and NE atoms in His residues.
The docking library for PTPRQ comprising about 260,000 synthetic and natural com-
pounds was constructed from the latest version of the chemical database distributed by
Interbioscreen (http://www.ibscreen.com) containing approximately 500,000 synthetic
and natural compounds. Prior to the virtual screening with docking simulations, they
were filtrated on the basis of Lipinski’s “Rule of Five” to adopt only the compounds with
the physicochemical properties of potential drug candidates [14] and without reactive
functional group(s). To remove the structural redundancies in the chemical library, struc-
turally similar compounds with a Tanimoto coefficient exceeding 0.85 were clustered into
a single representative molecule. Molecular similarities were measured using the finger-
prints of each molecule, generated using the Daylight software as an ASCII string of 1’s
and 0’s. In this way, a docking library consisting of 260,000 compounds was constructed.
All compounds included in the docking library were then processed with the CORINA
program to generate their 3D atomic coordinates, followed by the assignment of
Gasteiger-Marsilli atomic charges [15]. We used the AutoDock program [16] in the
virtual screening of PTPRQ inhibitors because the outperformance of its scoring func-
tion over those of the others had been shown in several target proteins [17]. AMBER
force field parameters were assigned for calculating the van der Waals interactions and
the internal energy of a ligand as implemented in the original AutoDock program.
Docking simulations with AutoDock were then carried out in the active site of PTPRQ
to score and rank the compounds in the docking library according to their calculated
binding affinities.
In the actual docking simulation of the compounds in the docking library, we used
the empirical AutoDock scoring function improved by the implementation of a new
solvation model for a compound. The modified scoring function can be expressed in
the following form.
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hydrogen bond, electrostatic interactions, torsional term, and desolvation energy of the
inhibitors, respectively. rij represents the interatomic distance, and Aij, Bij, Cij, and Dij
are related to the depths of the potential energy well and the equilibrium separations
between the two atoms. The hydrogen bond term has an additional weighting factor,
E(t), representing the angle-dependent directionality. Cubic equation approach was
applied to obtain the dielectric constant required in computing the interatomic
electrostatic interactions between PTPRQ and a ligand molecule [18]. In the en-
tropic term, Ntor is the number of rotatable bonds in the ligand. In the desolvation term,
Si and Vi are the solvation parameter and the fragmental volume of atom i [19], respect-
ively, while Oi
max stands for the maximum atomic occupancy. The self-solvation param-
eter Pi represents the extent of the stabilization of the solute atom i due to the
intramolecular interactions with the rest of solute atoms. Inclusion of this self-solvation
effect in the scoring function is necessary because the calculated molecular solvation free
energies were shown to be inaccurate in the absence of the self-solvation term [20]. To
calculate the contribution of molecular solvation free energy term in Eq. (1), we used the
atomic parameters developed by Choi and coworkers [20]. This modification of the solv-
ation free energy term is expected to increase the accuracy in virtual screening because
the underestimation of ligand solvation often leads to the overestimation of the binding
affinity of a ligand with many polar atoms [12].
The catalytic domain of PTPRQ (PTPRQ-C, residues 2661–2948) was subcloned into
pET28a and overexpressed using Escherichia coli BL21 (DE3) strain. Cells were grown
at 291 K after induction with 0.1 mM IPTG for 20 hours. His-tagged PTPRQ-C was
purified by nickel-affinity chromatography. 150 compounds selected from the prece-
dent virtual screening were evaluated for their in vitro inhibitory activity against the re-
combinant human PTPRQ. Initial inhibitor screening was performed by monitoring the
extent of hydrolysis of p-Nitrophenyl Phosphate (pNPP) with a spectrofluorometric
assay. The purified PTPRQ-C (1.5 μM), pNPP (5 mM), and a candidate inhibitor were
incubated in the reaction mixture containing 50 mM Bis-Tris (pH 6.0), 2 mM
dithiothreitol for 60 minutes. This enzymatic reaction was stopped with the addition of
sodium hydroxide (0.5 M). The phosphatase activities were then checked by the ab-
sorbance changes due to the hydrolysis of the substrate at 405 nm. IC50 values of the
inhibitors were determined from direct regression curve analysis.
Six PTPRQ inhibitors identified under the above reaction conditions were further in-
vestigated using PI(3,4,5)P3 as the substrate (Cayman Chemical). The enzymatic activity
of PTPRQ was measured in 80 μL reaction mixture containing 50 mM Tris–HCl
(pH 6.0), 10 mM dithiothreitol, 300 μM PI(3,4,5)P3, 100 μM inhibitor, and 1.5 μM of
the purified catalytic domain of PTPRQ. The mixture was incubated for 60 minutes at
310 K, and the enzymatic reaction was stopped by the addition of 20 μL of malachite
green/ammonium molybdate reagent (Bioassay systems). The absorbance was measured
at 650 nm using a plate reader.
Results and discussion
Of the 260,000 compounds screened with docking simulations in the active site of
PTPRQ, 150 top-scored compounds were selected as virtual hits. All of them were
available from the compound supplier and were tested for having the inhibitory activity
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pounds that inhibited the catalytic activity of PTPRQ by more than 50% at 100 μM,
which were selected to determine the IC50 values. The chemical structures and the in-
hibitory activities of the identified PTPRQ inhibitors are shown in Figure 1 and Table 1,
respectively. The structures of remaining 144 inactive compunds are also provided in
Additional file 1. We note that 1, 2, and 3–6 include pyrimidine-2,4,6-trione, 2-imino-
thiazolidin-4-one, and carboxylate moieties in the molecular structures, respectively.
These chemical groups are expected to serve as a surrogate for the substrate phosphate
group with negative charge. To the best of our knowledge, compounds 1–6 have not
been reported as a phosphatase inhibitor so far. In addition, no additional biological
activity was found for the six inhibitors at least in the two most popular chemical
databases, ChEMBL and PubChem.
As can be seen in Table 1, the potencies of the six PTPRQ inhibitors are moderate
with the IC50 values ranging from 29.9 to 85.7 μM. These modest inhibitory activities
can be understood because PTPRQ has a flat and shallow active site, which makes it
difficult for the inhibitors to be fully accommodated [21]. To improve the inhibitory
activities, therefore, some chemical groups should be added to 1–6 in such a way that
the resulting derivatives can be stabilized not only in the active site but also in other
peripheral binding pockets. Despite the modest inhibitor potencies, 1–6 deserve
consideration for further development by structure-activity relationship (SAR) studies
to optimize the antiobestic activities because they are structurally diverse and were
computationally screened for having desirable physicochemical properties as a drug
candidate.
To obtain structural insight into the inhibitory mechanisms of the identified PTPRQ
inhibitors, their binding modes in the active site were investigated in a comparative
fashion. Figure 2 shows the lowest-energy conformations of 1–6 in the active site gorge
of PTPRQ calculated with the modified AutoDock program. The results of these
docking simulations are self-consistent in the sense that the functional groups of simi-
lar chemical character are placed in similar ways with comparable interactions with theFigure 1 Chemical structures of the PTPRQ inhibitors identified from virtual screening.
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ample, the polar groups (pyrimidine-2,4,6-trione, 2-imino-thiazolidin-4-one, and carb-
oxylate moieties) point toward the catalytic cysteine residue (Cys2879) located at the
bottom of active site while the hydrophobic groups are directed to the WPD loop that
resides above the active site. These common features in the calculated binding modes
indicate that PTPRQ inhibitors should include an effective surrogate for the substrate
phosphate group and simultaneously the hydrophobic groups for binding to the WPD
loop. In order to examine the possibility of the allosteric inhibition of PTPRQ by 1–6,
docking simulations were carried out with the grid maps for the receptor model so as
to include the entire part of the catalytic domain of PTPRQ. However, the binding con-
figuration in which an inhibitor resides outside the active site was not observed for any
of the new inhibitors. These results support the possibility that the inhibitors would
impair the catalytic activity of PTPRQ through the specific binding in the active site.
Because PTPRQ functions on PIPs rather than the phosphorylated tyrosine, we also
examined whether 1–6 could inhibit the dephosphorylation activity of PTPRQ with re-
spect to the PI(3,4,5)P3 substrate. Under the enzymatic reaction condition including 1.5
μM PTPRQ-C, 300 μM PI(3,4,5)P3, and 100 μM inhibitor, 1 and 2 exhibit a significantFigure 2 Comparative view of the binding modes of the PTPRQ inhibitors. Carbon atoms of 1–6 are
indicated in green, cyan, black, gray, pink, and violet, respectively.
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and 6 in the reaction mixture have also an effect of reducing PTPRQ activity although
the extents of inhibition decrease significantly when compared to those of 1 and 2.
These results confirm that 1, 2, 3, and 6 are capable of impairing the enzymatic activity
of PTPRQ. However, the inhibitory activities 4 and 5 with respect to the catalytic
hydrolysis of PI(3,4,5)P3 by PTPRQ could not be measured due to their nonspecific
color reactions with the malachite green used for the detection of dephosphorylation.
The development of a new assay method is underway so that the inhibitory activities of
all putative inhibitors with respect to the lipid dephosphorylation of PTPRQ can be
measured successfully.
We now turn to the identification of the detailed interactions responsible for the
stabilization of PTPRQ inhibitors in the active site. The calculated binding mode of 1
in the active site is shown in Figure 4. The inhibitor appears to be in a close contact
with Cys2879–Arg2885, Trp2845–Val2850, and Gln2923–Gln2927, which belong to
the PTP, WPD, and Q loops, respectively. We note that the two aminocarbonyl oxygen
atoms of 1 receive the hydrogen bonds from the backbone amidic nitrogen of Ala2881
and the side-chain amidic nitrogen of Gln2927. These two hydrogen bonds seem to
play a role of anchor in positioning the inhibitor in the active site. It is also noteworthy
that the two aminocarbonyl oxygens of 1 reside in the vicinity of the side-chain thiolate
group of Cys2879 with the associated interatomic distances within 4.0 Å. Judging from
the proximity to Cys2879 and the formation of the multiple hydrogen bonds in the ac-
tive site, the pyrimidine-2,4,6-trione moiety of 1 is likely to serve as an effective surro-
gate for the substrate phosphate group. A stable hydrogen bond is also established
between the terminal ester group of 1 and the side-chain guanidinium ion of Arg2885.
The inhibitor 1 can be further stabilized in the active site of PTPRQ by van der Waals
interactions of its nonpolor groups with the hydrophobic side chains of Trp2845,
Pro2846, His2848, and Val2850. Thus, the overall structural features derived from
docking simulations indicate that the inhibitory activity of 1 stems from the multiple
hydrogen bonds and hydrophobic interactions established simultaneously in the active
site.
Figure 5 shows the lowest-energy binding mode of 2 in the active site of PTPRQ. The
binding mode of 2 differs from that of 1 in that the role of hydrogen bond donor withFigure 3 The inhibitory activity of 1, 2, 3, and 6 against the hydrolysis of PI(3,4,5)P3 by PTPRQ. The
enzymatic activity was assayed by monitoring the amount of released phosphate ion using malachite
green reagents.
Figure 4 Calculated binding mode of 1 in the active site of PTPRQ. Carbon atoms of the protein and
the ligand are indicated in cyan and green, respectively. Each dotted line indicates a hydrogen bond.
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of Arg2885 instead of Ala2881 and Gln2927. An additional hydrogen bond appears to
be established between the side-chain guanidinium ion of Arg2885 and the pyrazole
ring of 2, which should also be a significant binding force to stabilize the inhibitor in
the active site. It is noteworthy that the number of hydrogen bonds decreases from
three in the PTPRQ-1 to two in the PTPRQ-2 complex, which would have an effect of
lowering the inhibitory activity. Hydrophobic interactions in the PTPRQ-2 complex are
established in similar way to those in the PTPRQ-1 complex: two terminal phenyl rings
of 2 form the van der Waals contacts with the side chains of Trp2845, Pro2846,
His2848, and Val2850. Therefore, the relatively lower inhibitory activity of 2 than 1 can
be attributed to the loss of one hydrogen bond. Binding modes of 3–6 appear to be
similar to those of 1 and 2 in that the terminal carboxylate and the aromatic groupsFigure 5 Calculated binding mode of 2 in the active site of PTPRQ. Carbon atoms of the protein and
the ligand are indicated in cyan and green, respectively. Each dotted line indicates a hydrogen bond.
Table 2 Comparison of the inhibitory activities of 1–6 for PTPRQ and PTPRO
Compounds % inhibition at 100 μM for PTPRQ % inhibition at 100 μM for PTPRO
1 71.1 ± 0.8 94.4 ± 0.5
2 57.7 ± 0.4 94.2 ± 1.5
3 50.9 ± 2.2 48.7 ± 2.1
4 82.6 ± 0.2 95.0 ± 3.5
5 62.5 ± 1.6 95.0 ± 0.8
6 57.0 ± 2.1 81.2 ± 0.9
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loop and the hydrophobic interactions with nonpolar residues on the WPD loop,
respectively (data not shown here). It is thus found to be a common feature in binding
modes of 1–6 that multiple hydrogen bonds and hydrophobic interactions contribute
to the stabilization of the inhibitors in the active site of PTPRQ in a cooperative
fashion.
Because the selectivity has been one of the most important issues in the development
of phosphatase inhibitors, we compared the inhibitory activities of 1–6 for PTPRQ to
those for its homologous protein, PTP receptor type O (PTPRO). These inhibition
assays for selectivity were done in duplicates at the inhibitor concentration of 100 μM.
As can be seen in Table 2, all six compounds have a significant inhibitory activity
against both PTPRQ and PTPRO, which exemplifies the difficulty in the discovery of
specific inhibitors. The simultaneous inhibitions of PTPRQ and PTPRO by 1–6 are ac-
tually not surprising because they share a highly conserved catalytic module. To obtain
the specific inhibitors for PTPRQ, therefore, it seems that some chemical groups
should be added to 1–6 in such a way that the resulting derivatives can be stabilized
not only in the active site but also in other peripheral binding pockets.
Conclusions
In summary, we have identified six novel inhibitors of PTPRQ by applying a computer-
aided drug design protocol involving the structure-based virtual screening with docking
simulations under consideration of the effects of ligand solvation in the scoring func-
tion. These inhibitors are expected to have desirable physicochemical properties as a
drug candidate and reveal a moderate activity with IC50 values ranging from 29.9 to
85.7 μM. Therefore, each of the newly discovered inhibitors deserves consideration for
further development by SAR studies to optimize the antiobestic activities. The results
of binding mode analysis with docking simulations indicate that the inhibitors can be
stabilized in active site by the simultaneous establishment of multiple hydrogen bonds
and van der Waals contacts.Additional file
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